The International Centers for Precision Oncology (ICPO) Foundation and the World Federation of Nuclear Medicine and Biology (WFNMB) will partner to expand access to theranostics, particularly for patients in low- and middle-income countries.
The agreement, signed at the WFNMB Congress in Cartagena, Colombia, in February 2026, aims to improve clinical standards, advance research, and enhance education for healthcare professionals through the ICPO Academy for Theranostics, according to the organizations. The partnership also seeks to support implementation of World Health Assembly Resolution WHA78.13 on strengthening medical imaging capacity, which calls for coordinated efforts among professional organizations, industry, and policymakers to ensure equitable access to medical imaging and nuclear medicine worldwide.
"This collaboration reflects our shared commitment to advancing theranostics worldwide and will help address key health policy challenges while expanding equitable access to theranostics for patients globally," said Prof. Richard Baum, trustee of the ICPO Foundation and president of the ICPO Academy for Theranostics.
